Aurobindo Pharma Ltd has entered into a binding agreement with GLS Pharma Limited, a subsidiary of the company (GLS) and its promoters for acquisition of balance 5,90,361 equity shares of Rs. 10/- each (49% of GLS) for a purchase consideration of Rs. 22.5 crore. The shares are being acquired at a price of Rs. 381.12 per share. GLS will become a wholly owned subsidiary of the company post the acquisition.

GLS Pharma Limited (GLS) is a pharmaceutical company engaged in the business of Oncology products which include orals and injectables used in chemotherapy for solid malignancies, chemotherapy for hematological malignancies and chemo supportive products (Business).

GLS was incorporated on Sept 1, 2004 and initiated manufacturing in the year 2015. It had a total sales of Rs. 32.99 crores during FY 23-24, Rs. 36.08 crores during FY 22-23 and Rs. 25.84 crores during FY 21-22.